Surveillance of adverse events following immunisation in Australia annual report, 2017

Authors

  • Aditi Dey National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Sydney, Australia
  • Han Wang National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Sydney, Australia
  • Helen Quinn National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Sydney, Australia
  • Rona Hiam Pharmacovigilance and Special Access Branch, Therapeutic Goods Administration, Canberra, Australia
  • Nicholas Wood National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Sydney, Australia
  • Frank Beard National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Sydney, Australia
  • Kristine Macartney National Centre for Immunisation Research and Surveillance, University of Sydney and The Children’s Hospital at Westmead, Sydney, Australia

DOI:

https://doi.org/10.33321/cdi.2019.43.29

Keywords:

AEFI, adverse events, vaccines, surveillance, immunisation, vaccine

Abstract

This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) for 2017 reported to the Therapeutic Goods Administration and describes reporting trends over the 18-year period 1 January 2000 to 31 December 2017. There were 3,878 AEFI records for vaccines administered in 2017; an annual AEFI reporting rate of 15.8 per 100,000 population. There was a 12% increase in the overall AEFI reporting rate in 2017 compared with 2016. This increase in reported adverse events in 2017 compared to the previous year was likely due to the introduction of the zoster vaccine (Zostavax®) provided free for people aged 70–79 years under the National Immunisation Program (NIP) and also the state- and territory-based meningococcal ACWY conjugate vaccination programs. AEFI reporting rates for most other individual vaccines in 2017 were similar to 2016. The most commonly reported reactions were injection site reaction (34%), pyrexia (17%), rash (15%), vomiting (8%) and pain (7%). The majority of AEFI reports (88%) described non-serious events. Two deaths were reported that were determined to have a causal relationship with vaccination; they occurred in immunocompromised people contraindicated to receive the vaccines.

Downloads

Download data is not yet available.

References

Council for International Organizations of Medical Sciences (CIOMS) c/o World Health Organization. Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. 2012.

Dey A, Wang H, Quinn H, Hill R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2014. Commun Dis Intell Q Rep 2016;40(3):E377–90.

Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell Q Rep 2004;28(3):324–38.

Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell Q Rep 2006;30(3):319–33.

Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell Q Rep 2008;32(4):371–87.

Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell Q Rep 2003;27(3):307–23.

Lawrence GL, Aratchige PE, Boyd I, McIntyre PB, Gold MS. Annual report on surveillance of adverse events following immunisation in Australia, 2006. Commun Dis Intell Q Rep 2007;31(3):269–82.

Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004 Commun Dis Intell Q Rep 2005;29(3):248–62.

Mahajan D, Cook J, Dey A, Macartney K, Menzies R. Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2012. Commun Dis Intell Q Rep 2013;37(2):E130–4.

Mahajan D, Cook J, Dey A, Macartney K, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2011. Commun Dis Intell Q Rep 2012;36(4):E315–32.

Mahajan D, Cook J, McIntyre P, Macartney K, Menzies R. Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2011. Commun Dis Intell Q Rep 2012;36(1):114–9.

Mahajan D, Cook J, McIntyre PB, Macartney K, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2010. Commun Dis Intell Q Rep 2011;35(4):263–80.

Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep 2010;34(3):259–76.

Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell Q Rep 2009;33(4):365–81.

Mahajan D, Dey A, Cook J, Harvey B, Menzies R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2013. Commun Dis Intell Q Rep 2015;39(3):E369–86.

Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health, Canberra. 2018. Accessed on 17 January 2019. Available from: https://beta.health.gov.au/resources/publications/the-australian-immunisation-handbook

Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. Accessed on 9 July 2014. Available from: http://www.who-umc.org/

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)–United States, 1991–2001. [erratum appears in MMWR Morb Mortal Wkly Rep . 2003;52(06):113]. MMWR Surveill Summ 2003;52(1):1–24.

Brown EG. Using MedDRA: implications for risk management. Drug Saf 2004;27(8):591–602.

Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20(2):109–17.

National Health and Medical Research Council. The Australian Immunisation Handbook. 8th edn. Canberra: Australian Government Department of Health and Ageing; 2003.

Mahajan D, Dey A, Hill R, Harvey B, Menzies R, McIntyre P, et al. Methodological framework for reporting of adverse events following immunisation (AEFI) In: PHAA National Immunisation Conference, 17–19 June, 2014; Melbourne, Australia.

Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010–2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012;30(11):2020–3.

Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2011;205(5):e1–9.

Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2013;208(6):e1–6.

Australian Government Department of Health, Therapeutic Goods Administration. National Adverse Events Following Immunisation (AEFI) reporting form. Accessed on 26 March 2013. Available from: https://www.tga.gov.au/form/national-adverse-events-following-immunisation-aefi-reporting-form

SAS Institute Inc. The SAS system for Windows [computer program]. Version 9.4. Cary, N.C. 2012.

Australian Bureau of Statistics. Australian Demographic Statistics. 2015. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202015?OpenDocument#Time

Australian Government Department of Human Services. Australian Immunisation Register. Accessed on 21 October 2016. Available from: https://www.humanservices.gov.au/customer/services/medicare/australian-immunisation-register

Australian Government Department of Health. UPDATE: Expansion of Australia’s Immunisation Registers. Accessed on 21 October 2016. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/67D8681A67167949CA257E2E000EE07D/$File/Factsheet-%20Immunisation-Registers-Expansion-23102015.pdf

Varricchio F, Iskander J, DeStefano F, Ball R, Pless R, Braun M, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287–94.

Australian Government Department of Health, Therapeutic Goods Administration. Database of Adverse Event Notifications. Accessed on 26 March 2013. Available from: https://www.tga.gov.au/database-adverse-event-notifications-daen

Dey A, Wang H, Quinn H, Cook J, Macartney K. Surveillance of adverse events following immunisation in Australia, 2015. Communicable Diseases Intelligence Q Rep 2017;41:E264-78.

Simon LS. Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 2002;61(Suppl 2): ii88–9.

Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26(3):201–9.

Alexander KE, Tong PL, Macartney K, Beresford R, Sheppeard V, Gupta M. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine 2018;36(27):3890–3.

Rouse CE, Eckert LO, Babarinsa I, Fay E, Gupta M, Harrison MS, et al. Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine 2017;35(48 Pt A): 6563–74.

Ammon Avalos L, Galindo C, Li DK. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol. 2012;94(6):417–23.

Dey A, Wang H, Quinn H, Cook J, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2016. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00011-8

Mahajan D, Dey A, Cook J, Harvey B, Menzies R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2012. Commun Dis Intell Q Rep 2014;38(3):E232–46.

Gowland A, Hiam R, Behm C, Phillips A, Macartney K. Live vaccine administration to immunocompromised patients: use of active surveillance data to enhance vaccine signal investigation. Poster presentation. In: Asian Conference on Pharmacoepidemiology (ACPE); Brisbane.

National Centre for Immunisation Research and Surveillance. AusVaxSafety. Accessed on 20 September 2017. Available from: http://www.ausvaxsafety.org.au/safety-data

Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, et al. Herpes zoster vaccine live: A 10year review of post-marketing safety experience. Vaccine 2017;35(52):7231–9.

Therapeutic Goods Administration. Zostavax vaccine: Safety advisory – not to be used in patients with compromised immune function, 7 March 2017. Accessed on 29 November 2017. Available from: https://www.tga.gov.au/alert/zostavax-vaccine

Downloads

Published

16/07/19

How to Cite

Dey, Aditi, Han Wang, Helen Quinn, Rona Hiam, Nicholas Wood, Frank Beard, and Kristine Macartney. 2019. “Surveillance of Adverse Events Following Immunisation in Australia Annual Report, 2017”. Communicable Diseases Intelligence 43 (July). https://doi.org/10.33321/cdi.2019.43.29.

Issue

Vol. 43 (2019)

Section

Annual report

Categories

License

Copyright (c) 2019 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>